Loading…

A review of 18p deletions

Since 18p‐ was first described in 1963, much progress has been made in our understanding of this classic deletion condition. We have been able to establish a fairly complete picture of the phenotype when the deletion breakpoint occurs at the centromere, and we are working to establish the phenotypic...

Full description

Saved in:
Bibliographic Details
Published in:American journal of medical genetics. Part C, Seminars in medical genetics Seminars in medical genetics, 2015-09, Vol.169C (3), p.251-264
Main Authors: Hasi-Zogaj, Minire, Sebold, Courtney, Heard, Patricia, Carter, Erika, Soileau, Bridgette, Hill, Annice, Rupert, David, Perry, Brian, Atkinson, Sidney, O'Donnell, Louise, Gelfond, Jon, Lancaster, Jack, Fox, Peter T., Hale, Daniel E., Cody, Jannine D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3
cites cdi_FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3
container_end_page 264
container_issue 3
container_start_page 251
container_title American journal of medical genetics. Part C, Seminars in medical genetics
container_volume 169C
creator Hasi-Zogaj, Minire
Sebold, Courtney
Heard, Patricia
Carter, Erika
Soileau, Bridgette
Hill, Annice
Rupert, David
Perry, Brian
Atkinson, Sidney
O'Donnell, Louise
Gelfond, Jon
Lancaster, Jack
Fox, Peter T.
Hale, Daniel E.
Cody, Jannine D.
description Since 18p‐ was first described in 1963, much progress has been made in our understanding of this classic deletion condition. We have been able to establish a fairly complete picture of the phenotype when the deletion breakpoint occurs at the centromere, and we are working to establish the phenotypic effects when each gene on 18p is hemizygous. Our aim is to provide genotype‐specific anticipatory guidance and recommendations to families with an 18p‐ diagnosis. In addition, establishing the molecular underpinnings of the condition will potentially suggest targets for molecular treatments. Thus, the next step is to establish the precise effects of specific gene deletions. As we look forward to deepening our understanding of 18p‐, our focus will continue to be on the establishment of robust genotype–phenotype correlations and the penetrance of these phenotypes. We will continue to follow our 18p‐ cohort closely as they age to determine the presence or absence of some of these diagnoses, including spinocerebellar ataxia (SCA), facioscapulohumeral muscular dystrophy (FSHD), and dystonia. We will also continue to refine the critical regions for other phenotypes as we enroll additional (hopefully informative) participants into the research study and as the mechanisms of the genes in these regions are elucidated. Mouse models will also be developed to further our understanding of the effects of hemizygosity as well as to serve as models for treatment development. © 2015 Wiley Periodicals, Inc.
doi_str_mv 10.1002/ajmg.c.31445
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722179037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1710983738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3</originalsourceid><addsrcrecordid>eNqN0L9PwkAUB_CL0Yiim4uLIXFxsHi_7zoSIlWDmhANiculvd6ZYkvxjor89xYKDA7G6b3h877J-wJwhmAXQYhv4knx3tVdgihle-AIMYYDKgXf3-1ctsCx9xMICWRCHoIW5phBSdkROO91nPnKzKJT2g6Ss05qcjPPyqk_AQc2zr053cw2eB3cvvTvguFzdN_vDQPNIGMBCdOExYwgoinhnCOrJQqJFVZjS7S11GpDLSHcWp5SrI2ULJWJMRrZkCekDa6a3JkrPyvj56rIvDZ5Hk9NWXmFBMZIhJCIf1AEQ1lDWdPLX3RSVm5aP7JWiEqCYK2uG6Vd6b0zVs1cVsRuqRBUq3bVql2l1brdml9sQqukMOkOb-usAW3AIsvN8s8w1Xt4jPrb3KA5y_zcfO_OYvehuCCCqfFTpMgbGg9G0UiNyQ_LOpHn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710148310</pqid></control><display><type>article</type><title>A review of 18p deletions</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Hasi-Zogaj, Minire ; Sebold, Courtney ; Heard, Patricia ; Carter, Erika ; Soileau, Bridgette ; Hill, Annice ; Rupert, David ; Perry, Brian ; Atkinson, Sidney ; O'Donnell, Louise ; Gelfond, Jon ; Lancaster, Jack ; Fox, Peter T. ; Hale, Daniel E. ; Cody, Jannine D.</creator><creatorcontrib>Hasi-Zogaj, Minire ; Sebold, Courtney ; Heard, Patricia ; Carter, Erika ; Soileau, Bridgette ; Hill, Annice ; Rupert, David ; Perry, Brian ; Atkinson, Sidney ; O'Donnell, Louise ; Gelfond, Jon ; Lancaster, Jack ; Fox, Peter T. ; Hale, Daniel E. ; Cody, Jannine D.</creatorcontrib><description>Since 18p‐ was first described in 1963, much progress has been made in our understanding of this classic deletion condition. We have been able to establish a fairly complete picture of the phenotype when the deletion breakpoint occurs at the centromere, and we are working to establish the phenotypic effects when each gene on 18p is hemizygous. Our aim is to provide genotype‐specific anticipatory guidance and recommendations to families with an 18p‐ diagnosis. In addition, establishing the molecular underpinnings of the condition will potentially suggest targets for molecular treatments. Thus, the next step is to establish the precise effects of specific gene deletions. As we look forward to deepening our understanding of 18p‐, our focus will continue to be on the establishment of robust genotype–phenotype correlations and the penetrance of these phenotypes. We will continue to follow our 18p‐ cohort closely as they age to determine the presence or absence of some of these diagnoses, including spinocerebellar ataxia (SCA), facioscapulohumeral muscular dystrophy (FSHD), and dystonia. We will also continue to refine the critical regions for other phenotypes as we enroll additional (hopefully informative) participants into the research study and as the mechanisms of the genes in these regions are elucidated. Mouse models will also be developed to further our understanding of the effects of hemizygosity as well as to serve as models for treatment development. © 2015 Wiley Periodicals, Inc.</description><identifier>ISSN: 1552-4868</identifier><identifier>EISSN: 1552-4876</identifier><identifier>DOI: 10.1002/ajmg.c.31445</identifier><identifier>PMID: 26250845</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>18p ; 18p deletion ; Abnormalities, Multiple - diagnosis ; Abnormalities, Multiple - etiology ; Abnormalities, Multiple - therapy ; Animals ; Chromosome Deletion ; Chromosomes, Human, Pair 18 - genetics ; Genetics ; Genotype ; Humans ; Mice ; monosomy 18p ; Phenotype</subject><ispartof>American journal of medical genetics. Part C, Seminars in medical genetics, 2015-09, Vol.169C (3), p.251-264</ispartof><rights>2015 Wiley Periodicals, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3</citedby><cites>FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26250845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasi-Zogaj, Minire</creatorcontrib><creatorcontrib>Sebold, Courtney</creatorcontrib><creatorcontrib>Heard, Patricia</creatorcontrib><creatorcontrib>Carter, Erika</creatorcontrib><creatorcontrib>Soileau, Bridgette</creatorcontrib><creatorcontrib>Hill, Annice</creatorcontrib><creatorcontrib>Rupert, David</creatorcontrib><creatorcontrib>Perry, Brian</creatorcontrib><creatorcontrib>Atkinson, Sidney</creatorcontrib><creatorcontrib>O'Donnell, Louise</creatorcontrib><creatorcontrib>Gelfond, Jon</creatorcontrib><creatorcontrib>Lancaster, Jack</creatorcontrib><creatorcontrib>Fox, Peter T.</creatorcontrib><creatorcontrib>Hale, Daniel E.</creatorcontrib><creatorcontrib>Cody, Jannine D.</creatorcontrib><title>A review of 18p deletions</title><title>American journal of medical genetics. Part C, Seminars in medical genetics</title><addtitle>Am. J. Med. Genet</addtitle><description>Since 18p‐ was first described in 1963, much progress has been made in our understanding of this classic deletion condition. We have been able to establish a fairly complete picture of the phenotype when the deletion breakpoint occurs at the centromere, and we are working to establish the phenotypic effects when each gene on 18p is hemizygous. Our aim is to provide genotype‐specific anticipatory guidance and recommendations to families with an 18p‐ diagnosis. In addition, establishing the molecular underpinnings of the condition will potentially suggest targets for molecular treatments. Thus, the next step is to establish the precise effects of specific gene deletions. As we look forward to deepening our understanding of 18p‐, our focus will continue to be on the establishment of robust genotype–phenotype correlations and the penetrance of these phenotypes. We will continue to follow our 18p‐ cohort closely as they age to determine the presence or absence of some of these diagnoses, including spinocerebellar ataxia (SCA), facioscapulohumeral muscular dystrophy (FSHD), and dystonia. We will also continue to refine the critical regions for other phenotypes as we enroll additional (hopefully informative) participants into the research study and as the mechanisms of the genes in these regions are elucidated. Mouse models will also be developed to further our understanding of the effects of hemizygosity as well as to serve as models for treatment development. © 2015 Wiley Periodicals, Inc.</description><subject>18p</subject><subject>18p deletion</subject><subject>Abnormalities, Multiple - diagnosis</subject><subject>Abnormalities, Multiple - etiology</subject><subject>Abnormalities, Multiple - therapy</subject><subject>Animals</subject><subject>Chromosome Deletion</subject><subject>Chromosomes, Human, Pair 18 - genetics</subject><subject>Genetics</subject><subject>Genotype</subject><subject>Humans</subject><subject>Mice</subject><subject>monosomy 18p</subject><subject>Phenotype</subject><issn>1552-4868</issn><issn>1552-4876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqN0L9PwkAUB_CL0Yiim4uLIXFxsHi_7zoSIlWDmhANiculvd6ZYkvxjor89xYKDA7G6b3h877J-wJwhmAXQYhv4knx3tVdgihle-AIMYYDKgXf3-1ctsCx9xMICWRCHoIW5phBSdkROO91nPnKzKJT2g6Ss05qcjPPyqk_AQc2zr053cw2eB3cvvTvguFzdN_vDQPNIGMBCdOExYwgoinhnCOrJQqJFVZjS7S11GpDLSHcWp5SrI2ULJWJMRrZkCekDa6a3JkrPyvj56rIvDZ5Hk9NWXmFBMZIhJCIf1AEQ1lDWdPLX3RSVm5aP7JWiEqCYK2uG6Vd6b0zVs1cVsRuqRBUq3bVql2l1brdml9sQqukMOkOb-usAW3AIsvN8s8w1Xt4jPrb3KA5y_zcfO_OYvehuCCCqfFTpMgbGg9G0UiNyQ_LOpHn</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Hasi-Zogaj, Minire</creator><creator>Sebold, Courtney</creator><creator>Heard, Patricia</creator><creator>Carter, Erika</creator><creator>Soileau, Bridgette</creator><creator>Hill, Annice</creator><creator>Rupert, David</creator><creator>Perry, Brian</creator><creator>Atkinson, Sidney</creator><creator>O'Donnell, Louise</creator><creator>Gelfond, Jon</creator><creator>Lancaster, Jack</creator><creator>Fox, Peter T.</creator><creator>Hale, Daniel E.</creator><creator>Cody, Jannine D.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201509</creationdate><title>A review of 18p deletions</title><author>Hasi-Zogaj, Minire ; Sebold, Courtney ; Heard, Patricia ; Carter, Erika ; Soileau, Bridgette ; Hill, Annice ; Rupert, David ; Perry, Brian ; Atkinson, Sidney ; O'Donnell, Louise ; Gelfond, Jon ; Lancaster, Jack ; Fox, Peter T. ; Hale, Daniel E. ; Cody, Jannine D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>18p</topic><topic>18p deletion</topic><topic>Abnormalities, Multiple - diagnosis</topic><topic>Abnormalities, Multiple - etiology</topic><topic>Abnormalities, Multiple - therapy</topic><topic>Animals</topic><topic>Chromosome Deletion</topic><topic>Chromosomes, Human, Pair 18 - genetics</topic><topic>Genetics</topic><topic>Genotype</topic><topic>Humans</topic><topic>Mice</topic><topic>monosomy 18p</topic><topic>Phenotype</topic><toplevel>online_resources</toplevel><creatorcontrib>Hasi-Zogaj, Minire</creatorcontrib><creatorcontrib>Sebold, Courtney</creatorcontrib><creatorcontrib>Heard, Patricia</creatorcontrib><creatorcontrib>Carter, Erika</creatorcontrib><creatorcontrib>Soileau, Bridgette</creatorcontrib><creatorcontrib>Hill, Annice</creatorcontrib><creatorcontrib>Rupert, David</creatorcontrib><creatorcontrib>Perry, Brian</creatorcontrib><creatorcontrib>Atkinson, Sidney</creatorcontrib><creatorcontrib>O'Donnell, Louise</creatorcontrib><creatorcontrib>Gelfond, Jon</creatorcontrib><creatorcontrib>Lancaster, Jack</creatorcontrib><creatorcontrib>Fox, Peter T.</creatorcontrib><creatorcontrib>Hale, Daniel E.</creatorcontrib><creatorcontrib>Cody, Jannine D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of medical genetics. Part C, Seminars in medical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasi-Zogaj, Minire</au><au>Sebold, Courtney</au><au>Heard, Patricia</au><au>Carter, Erika</au><au>Soileau, Bridgette</au><au>Hill, Annice</au><au>Rupert, David</au><au>Perry, Brian</au><au>Atkinson, Sidney</au><au>O'Donnell, Louise</au><au>Gelfond, Jon</au><au>Lancaster, Jack</au><au>Fox, Peter T.</au><au>Hale, Daniel E.</au><au>Cody, Jannine D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of 18p deletions</atitle><jtitle>American journal of medical genetics. Part C, Seminars in medical genetics</jtitle><addtitle>Am. J. Med. Genet</addtitle><date>2015-09</date><risdate>2015</risdate><volume>169C</volume><issue>3</issue><spage>251</spage><epage>264</epage><pages>251-264</pages><issn>1552-4868</issn><eissn>1552-4876</eissn><abstract>Since 18p‐ was first described in 1963, much progress has been made in our understanding of this classic deletion condition. We have been able to establish a fairly complete picture of the phenotype when the deletion breakpoint occurs at the centromere, and we are working to establish the phenotypic effects when each gene on 18p is hemizygous. Our aim is to provide genotype‐specific anticipatory guidance and recommendations to families with an 18p‐ diagnosis. In addition, establishing the molecular underpinnings of the condition will potentially suggest targets for molecular treatments. Thus, the next step is to establish the precise effects of specific gene deletions. As we look forward to deepening our understanding of 18p‐, our focus will continue to be on the establishment of robust genotype–phenotype correlations and the penetrance of these phenotypes. We will continue to follow our 18p‐ cohort closely as they age to determine the presence or absence of some of these diagnoses, including spinocerebellar ataxia (SCA), facioscapulohumeral muscular dystrophy (FSHD), and dystonia. We will also continue to refine the critical regions for other phenotypes as we enroll additional (hopefully informative) participants into the research study and as the mechanisms of the genes in these regions are elucidated. Mouse models will also be developed to further our understanding of the effects of hemizygosity as well as to serve as models for treatment development. © 2015 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26250845</pmid><doi>10.1002/ajmg.c.31445</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1552-4868
ispartof American journal of medical genetics. Part C, Seminars in medical genetics, 2015-09, Vol.169C (3), p.251-264
issn 1552-4868
1552-4876
language eng
recordid cdi_proquest_miscellaneous_1722179037
source Wiley-Blackwell Read & Publish Collection
subjects 18p
18p deletion
Abnormalities, Multiple - diagnosis
Abnormalities, Multiple - etiology
Abnormalities, Multiple - therapy
Animals
Chromosome Deletion
Chromosomes, Human, Pair 18 - genetics
Genetics
Genotype
Humans
Mice
monosomy 18p
Phenotype
title A review of 18p deletions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A26%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%2018p%20deletions&rft.jtitle=American%20journal%20of%20medical%20genetics.%20Part%20C,%20Seminars%20in%20medical%20genetics&rft.au=Hasi-Zogaj,%20Minire&rft.date=2015-09&rft.volume=169C&rft.issue=3&rft.spage=251&rft.epage=264&rft.pages=251-264&rft.issn=1552-4868&rft.eissn=1552-4876&rft_id=info:doi/10.1002/ajmg.c.31445&rft_dat=%3Cproquest_cross%3E1710983738%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5055-39db5a5313c436661fc8193f7fc2f3cff4fce4f336ff6d42ce885d8beec1f96b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1710148310&rft_id=info:pmid/26250845&rfr_iscdi=true